Clinical Trial Update: Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response [Phase 3]

View source ↗

Summary

Phase 3 clinical trial exploring switching from docetaxel to androgen receptor pathway inhibitors in metastatic castration-sensitive prostate cancer patients wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-sensitive Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Androgen receptor pathway inhibitors
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Canadian Cancer Trials Group | Conditions: Prostate Cancer (Adenocarcinoma) | Phase 3 | Status: RECRUITING